Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Windtree Therapeutics Inc is a biotechnology business based in the US. Windtree Therapeutics shares (WINT) are listed on the NASDAQ and all prices are listed in US Dollars. Windtree Therapeutics employs 33 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Active traders
| Latest market close | $0.46 |
|---|---|
| 52-week range | $0.38 - $2.40 |
| 50-day moving average | $0.55 |
| 200-day moving average | $1.24 |
| Wall St. target price | $3.40 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.44 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.4641 from 2022-07-06
| 1 week (2022-06-30) | 10.50% |
|---|---|
| 1 month (2022-06-07) | -1.46% |
| 3 months (2022-04-03) | N/A |
| 6 months (2022-01-06) | -67.77% |
| 1 year (2021-07-07) | -77.47% |
|---|---|
| 2 years (2020-07-07) | -93.37% |
| 3 years (2019-07-03) | N/A |
| 5 years (2017-07-07) | 62.84% |
| Gross profit TTM | $-17,787,000 |
|---|---|
| Return on assets TTM | -19.16% |
| Return on equity TTM | -105.85% |
| Profit margin | 0% |
| Book value | $1.22 |
| Market capitalisation | $12.5 million |
TTM: trailing 12 months
We're not expecting Windtree Therapeutics to pay a dividend over the next 12 months.
Windtree Therapeutics's shares were split on a 1:3 basis on 28 April 2020. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Windtree Therapeutics shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Windtree Therapeutics shares which in turn could have impacted Windtree Therapeutics's share price.
Over the last 12 months, Windtree Therapeutics's shares have ranged in value from as little as $0.38 up to $2.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Windtree Therapeutics's is 0.2799. This would suggest that Windtree Therapeutics's shares are less volatile than average (for this exchange).
Windtree Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S. A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.